{"entity":{"id":"nct07276373","kind":"trial","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Corcept Therapeutics, now recruiting.","summary":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07276373 by Corcept Therapeutics, with 50 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09. Interventions recorded: Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg and Nivolumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07276373","url":"https://clinicaltrials.gov/study/NCT07276373"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["corcept"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07276373","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies","sponsor":"Corcept Therapeutics","enrolled":50,"outcomes":[]},"route":"/trials/nct07276373/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/"}]}}